Negocie Vir Biotechnology VIR

Venda
 Comprar

Gráfico VirBiotechnology ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

VirBiotechnology news

Últimas notícias

Mostrar mais
Frances Wang 2025 Maio 27, 16:00

GOOGL Share Price Analysis: Why Alphabet Stock Is Up Today?

Stocks
Frances Wang 2025 Maio 27, 16:00

Stock market today: Hang Seng Dips, Nikkei Gains. Dow jumps

Stocks
Tommy Yap 2025 Maio 27, 16:00

Morning Note: RBNZ Eases Policy; Aussie Inflation Surprises; Tesla Struggles in Europe

Morning Note
Tommy Yap 2025 Maio 26, 16:00

Morning Note: Gold Awaits Fed Clues; Japan Fiscal Strain; SNB Hints More Cuts

Morning Note Commodities
Ghko B 2025 Maio 25, 16:00

Stock Market Updates: Sensex jumps 300 pts, Nifty over 24,900; NTPC gains 2%

Stocks
Ghko B 2025 Maio 25, 16:00

TEM stock price forecast: Is TEM a good stock to buy?

Stocks
Tommy Yap 2025 Maio 25, 16:00

Morning Note: Trump's Tariff Delays Boost Oil & Euro; New iPhone Tariff Threat

Morning Note Commodities EUR AAPL
Australia CPI
Tommy Yap 2025 Maio 24, 21:00

Week Ahead: Australia CPI and RBNZ Interest Rate Decision in Spotlight

Forex Indices

Info

Spread

0.03

Spread (%)

0.6369 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercado aberto

Quarta-feira

13:31 - 19:59

Segunda-feira

13:31-19:59

Terça-feira

13:31-19:59

Quinta-feira

13:31-19:59

Sexta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

644189056

Ações em circulação

138238000

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

Data Ex-Dividendos

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-4.23

Saiba mais sobre este instrumento

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot